Comparative Pharmacology
Head-to-head clinical analysis: DORYX versus DOXY 200.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DORYX versus DOXY 200.
DORYX vs DOXY 200
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the addition of amino acids to the growing peptide chain.
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex, and thus inhibiting peptide chain elongation. It is bacteriostatic and active against a broad range of gram-positive and gram-negative bacteria, as well as atypical organisms.
100 mg orally every 12 hours on day 1, then 100 mg orally every 24 hours. For severe infections: 100 mg orally every 12 hours.
200 mg orally once daily or 100 mg orally every 12 hours.
None Documented
None Documented
Terminal elimination half-life is 18-22 hours in healthy adults; prolonged to 21-36 hours in renal impairment; clinically relevant for once-daily dosing and monitoring for accumulation.
Terminal elimination half-life: 18–22 hours in adults with normal renal function; prolonged in renal impairment (up to 40 hours).
Renal (40-60% as unchanged drug via glomerular filtration), biliary/fecal (20-30% as active and inactive metabolites), incomplete excretion leads to enterohepatic recirculation.
Renal: 40% unchanged via glomerular filtration; Biliary/fecal: 20–25% as active drug and metabolites; remainder as inactive metabolites.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic